Graybug Vision Reports Full-Data Analysis from 12-Month Treatment Phase of ALTISSIMO Phase 2b Trial in Wet AMD
12 mai 2021 07h00 HE
|
Graybug Vision, Inc.
GB-102 1mg has shown competitive durability and anatomical control versus afliberceptTrend in mean BCVA of GB-102 1mg compared to aflibercept driven primarily by a subgroup of patientsDeveloping...
Graybug Vision Reports Preliminary Topline Results from Phase 2b ALTISSIMO Trial
09 mars 2021 07h30 HE
|
Graybug Vision, Inc.
Median time to first supportive therapy was 5 months for GB-102 1mg48% of patients in the GB-102 1 mg arm were rescue-free for at least 6 monthsControl of retinal thickness was consistent across all...
Graybug Vision Announces Full Year 2020 Financial Results and Recent Corporate Developments
04 mars 2021 17h04 HE
|
Graybug Vision, Inc.
REDWOOD CITY, Calif., March 04, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the...
Graybug Vision to Participate in SVB Leerink Global Healthcare Conference
17 févr. 2021 07h30 HE
|
Graybug Vision, Inc.
REDWOOD CITY, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines to treat...
Graybug Vision Appoints Bettina Maunz as Chief People Officer, Expanding the Company’s Executive Team
01 févr. 2021 07h30 HE
|
Graybug Vision, Inc.
REDWOOD CITY, Calif., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines to treat...
Graybug Vision Completes Treatment Phase of ALTISSIMO Trial in Wet AMD with 12-Month Topline Data Expected in Second Quarter 2021
07 janv. 2021 07h30 HE
|
Graybug Vision, Inc.
REDWOOD CITY, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines to treat...
Graybug Vision to Participate in the 32nd Annual Piper Sandler Healthcare Conference
16 nov. 2020 16h05 HE
|
Graybug Vision, Inc.
REDWOOD CITY, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the...
Graybug Vision Announces Financial Results for the Three and Nine Months Ended September 30, 2020 and Recent Corporate Developments
12 nov. 2020 16h05 HE
|
Graybug Vision, Inc.
REDWOOD CITY, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the...
Graybug Appoints Three New Members to its Board of Directors
25 sept. 2020 08h00 HE
|
Graybug Vision, Inc.
REDWOOD CITY, Calif., Sept. 25, 2020 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines to treat...
Graybug Vision Announces Pricing of Upsized Initial Public Offering
24 sept. 2020 20h12 HE
|
Graybug Vision, Inc.
REDWOOD CITY, Calif., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines to treat...